• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis.

作者信息

Vansteenkiste Johan

机构信息

Respiratory Oncology Unit, Department of Respiratory Medicine, Katholieke Universiteit Leuven, Leuven, Belgium.

出版信息

ESMO Open. 2017 Mar 7;2(Suppl 1):e000119. doi: 10.1136/esmoopen-2016-000119. eCollection 2017.

DOI:10.1136/esmoopen-2016-000119
PMID:29147577
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5682357/
Abstract
摘要

相似文献

1
Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis.纳武单抗用于日本非小细胞肺癌患者：疗效相似，但需警惕肺炎。
ESMO Open. 2017 Mar 7;2(Suppl 1):e000119. doi: 10.1136/esmoopen-2016-000119. eCollection 2017.
2
Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer.纳武单抗治疗前放射性肺炎病史与经治晚期非小细胞肺癌患者间质性肺疾病的发生及无进展生存期的相关性
Anticancer Res. 2017 Sep;37(9):5199-5205. doi: 10.21873/anticanres.11943.
3
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.纳武利尤单抗治疗经治非小细胞肺癌患者的有效性和安全性：一项多中心回顾性队列研究。
Lung Cancer. 2018 May;119:14-20. doi: 10.1016/j.lungcan.2018.02.017. Epub 2018 Mar 2.
4
A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.纳武单抗治疗轻度特发性间质性肺炎的晚期非小细胞肺癌患者的一项试点试验。
Lung Cancer. 2017 Sep;111:1-5. doi: 10.1016/j.lungcan.2017.06.008. Epub 2017 Jun 17.
5
Pneumonitis in Irradiated Lungs After Nivolumab: A Brief Communication and Review of the Literature.尼妥珠单抗联合放疗治疗食管癌的临床疗效观察
J Immunother. 2018 Feb/Mar;41(2):96-99. doi: 10.1097/CJI.0000000000000198.
6
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease.纳武利尤单抗治疗伴预先存在的间质性肺病的非小细胞肺癌的疗效和安全性。
Thorac Cancer. 2018 Jul;9(7):847-855. doi: 10.1111/1759-7714.12759. Epub 2018 May 21.
7
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.nivolumab 联合标准一线放化疗方案同期用于 III 期非小细胞肺癌的安全性评价：ETOP NICOLAS 试验。
Lung Cancer. 2019 Jul;133:83-87. doi: 10.1016/j.lungcan.2019.05.001. Epub 2019 May 3.
8
Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.两项 nivolumab 治疗既往接受治疗的晚期非小细胞肺癌日本患者的 II 期研究的 3 年随访结果：ONO-4538-05 和 ONO-4538-06 研究的汇总分析。
Cancer Med. 2019 Sep;8(11):5183-5193. doi: 10.1002/cam4.2411. Epub 2019 Jul 29.
9
Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.纳武利尤单抗治疗伴有轻度特发性间质性肺炎的晚期非小细胞肺癌患者：一项多中心、开放标签、单臂 II 期试验。
Lung Cancer. 2019 Aug;134:274-278. doi: 10.1016/j.lungcan.2019.06.001. Epub 2019 Jun 3.
10
High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.纳武利尤单抗致肺炎的高发生率和早发性：4 例病例报告及文献复习。
BMC Pulm Med. 2018 Jan 30;18(1):23. doi: 10.1186/s12890-018-0592-x.

引用本文的文献

1
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.一线纳武利尤单抗联合伊匹单抗加或不加化疗治疗日本非小细胞肺癌患者：LIGHT-NING 研究。
Jpn J Clin Oncol. 2024 Apr 6;54(4):452-462. doi: 10.1093/jjco/hyad195.
2
Drug-induced interstitial lung disease after chemoimmunotherapy for extensive-stage small cell lung cancer.广泛期小细胞肺癌化疗免疫治疗后药物性间质性肺疾病
Heliyon. 2023 Sep 26;9(10):e20463. doi: 10.1016/j.heliyon.2023.e20463. eCollection 2023 Oct.
3
Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective.曲妥珠单抗-德鲁替康（T-DXd）治疗相关肺毒性的管理：加拿大视角。
Curr Oncol. 2023 Aug 30;30(9):8019-8038. doi: 10.3390/curroncol30090582.
4
Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.曲妥珠单抗衍生物治疗人表皮生长因子受体 2 表达转移性乳腺癌相关间质性肺病/肺炎的真实世界观点和实践。
JCO Oncol Pract. 2023 Aug;19(8):539-546. doi: 10.1200/OP.22.00480. Epub 2023 May 19.
5
An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870).一项针对接受二线纳武利尤单抗单药治疗的亚洲晚期非小细胞肺癌患者的开放标签安全性研究（CheckMate 870）。
Ther Adv Med Oncol. 2022 Nov 19;14:17588359221138380. doi: 10.1177/17588359221138380. eCollection 2022.
6
Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study.免疫相关不良事件与接受免疫治疗加化疗的非小细胞肺癌患者的临床获益相关：一项回顾性研究。
Front Oncol. 2021 Mar 23;11:630136. doi: 10.3389/fonc.2021.630136. eCollection 2021.
7
Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation.免疫检查点抑制剂诱发的肺炎：从临床数据到转化研究
Front Oncol. 2020 Sep 11;10:1785. doi: 10.3389/fonc.2020.01785. eCollection 2020.

本文引用的文献

1
Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer.纳武利尤单抗用于日本晚期或复发性非鳞状非小细胞肺癌患者的多中心II期研究。
ESMO Open. 2017 Mar 7;1(4):e000108. doi: 10.1136/esmoopen-2016-000108. eCollection 2016.
2
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.帕博利珠单抗对比多西他赛用于治疗后 PD-L1 阳性的、晚期非小细胞肺癌（KEYNOTE-010）：一项随机对照试验。
Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.
3
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
4
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.纳武单抗与多西他赛治疗晚期鳞状细胞非小细胞肺癌的疗效比较
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
5
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.吉非替尼和厄洛替尼治疗晚期非小细胞肺癌的间质性肺病风险：临床试验的系统评价和荟萃分析。
Lung Cancer. 2014 Feb;83(2):231-9. doi: 10.1016/j.lungcan.2013.11.016. Epub 2013 Nov 27.
6
Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.多西他赛致严重中性粒细胞减少的药物人种学：已发表的 II 期和 III 期试验综合分析。
Int J Clin Oncol. 2013 Feb;18(1):96-104. doi: 10.1007/s10147-011-0349-5. Epub 2011 Nov 18.
7
Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124.广泛期小细胞肺癌中顺铂+伊立替康与顺铂+依托泊苷的3期试验的常见手臂比较结局分析：日本临床肿瘤学会9511和西南肿瘤协作组0124的最终患者水平结果
Cancer. 2010 Dec 15;116(24):5710-5. doi: 10.1002/cncr.25532. Epub 2010 Aug 24.
8
Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era.与白种人相比，在口服表皮生长因子受体酪氨酸激酶抑制剂时代之前和之后，韩国人种是非小细胞肺癌总生存的独立有利预后因素。
J Thorac Oncol. 2010 Aug;5(8):1185-96. doi: 10.1097/JTO.0b013e3181e2f624.
9
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.日本-美国关于紫杉醇联合卡铂治疗晚期非小细胞肺癌的共同对照分析：一种评估群体相关药物基因组学的模型
J Clin Oncol. 2009 Jul 20;27(21):3540-6. doi: 10.1200/JCO.2008.20.8793. Epub 2009 May 26.
10
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.伊立替康/顺铂与依托泊苷/顺铂治疗广泛期小细胞肺癌的III期试验：SWOG S0124的临床和药物基因组学结果
J Clin Oncol. 2009 May 20;27(15):2530-5. doi: 10.1200/JCO.2008.20.1061. Epub 2009 Apr 6.